Literature DB >> 10370001

Endovascular treatment of superior vena cava obstruction in patients with malignancies.

F Thony1, D Moro, P Witmeyer, S Angiolini, C Brambilla, M Coulomb, G Ferretti.   

Abstract

The aim of this study was to report our experience on the management of superior vena cava obstruction (SVCO) secondary to malignant disease, using endovascular procedures. Twenty-six patients with SVCO due to primary or secondary tumors of the lung or the mediastinum, or catheter inserted for treatment of an extra-thoracic neoplasm, had an endovascular therapy which consisted of stenting, angioplasty, thrombo-aspiration or local fibrinolysis. Immediately after the procedure, rapid relief of symptoms occurred in 24 (90 %) of the patients. The mean Kishi's score decreased from 5.5 to 0.96. Immediate complications included one death related to pericarditis bleeding following fibrinolysis. Three patients relapsed after 20 days, 4 months and 6 months, and needed a second stenting. At 6 months the primary patency rate was 83 % and the secondary patency rate was 89 %. Endovascular treatment of SVCOs is a simple and safe procedure to restore the patency of the superior vena cava in malignant SVCO. It should be indicated in most cases as first-line treatment and performed as early as possible.

Entities:  

Mesh:

Year:  1999        PMID: 10370001     DOI: 10.1007/s003300050777

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  10 in total

1.  Endovascular stent-based revascularization of malignant superior vena cava syndrome with concomitant implantation of a port device using a dual venous approach.

Authors:  Susanne Anton; T Oechtering; E Stahlberg; F Jacob; M Kleemann; J Barkhausen; J P Goltz
Journal:  Support Care Cancer       Date:  2017-12-22       Impact factor: 3.603

2.  Antithrombotic Therapy Post Endovascular Stenting for Superior Vena Cava Syndrome.

Authors:  Michael J Scalese; Sheena L Hayes; Sara Lott
Journal:  Hosp Pharm       Date:  2017-08-14

3.  Superior vena caval bypass using the superficial femoral vein for treatment of superior vena cava syndrome.

Authors:  Gregory N Messner; Ali Azizzadeh; T Tam Huynh; Anthony L Estrera; Eyal E Porat; Hazim J Safi
Journal:  Tex Heart Inst J       Date:  2005

4.  Endovascular therapy for palliative care of cancer patients.

Authors:  Kush R Desai; Richard I Chen
Journal:  Semin Intervent Radiol       Date:  2007-12       Impact factor: 1.513

Review 5.  Central venous access: techniques and indications in oncology.

Authors:  Pierre-Yves Marcy
Journal:  Eur Radiol       Date:  2008-05-06       Impact factor: 5.315

6.  Massive thrombosis of brachiocephalic veins and superior vena cava syndrome in a patient with non-small cell lung cancer treated with the epidermal growth factor receptor inhibitor erlotinib.

Authors:  Raffaella Salmi; Piergiorgio Gaudenzi; Filippo Di Todaro; Pierluigi Morandi; Ingrid Nielsen; Roberto Manfredini
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

7.  Subclavian thrombosis in a patient with advanced lung cancer: a case report.

Authors:  Paul Zarogoulidis; Eirini Terzi; Georgios Kouliatsis; Vasilis Zervas; Theodoros Kontakiotis; Alexandros Mitrakas; Kostas Zarogoulidis
Journal:  J Med Case Rep       Date:  2011-05-06

8.  Malignant thrombosis of the superior vena cava caused by non-small-cell lung cancer treated with radiation and erlotinib: a case with complete and prolonged response over 3 years.

Authors:  Jianyang Wang; Jun Liang; Wenqing Wang; Han Ouyang; Luhua Wang
Journal:  Onco Targets Ther       Date:  2013-07-01       Impact factor: 4.147

9.  Endovascular therapy for superior vena cava syndrome: A systematic review and meta-analysis.

Authors:  Abdul Hussain Azizi; Irfan Shafi; Matthew Zhao; Saurav Chatterjee; Stephanie Clare Roth; Maninder Singh; Vladimir Lakhter; Riyaz Bashir
Journal:  EClinicalMedicine       Date:  2021-06-28

Review 10.  Endovascular Stenting in Superior Vena Cava Syndrome: A Systematic Review and Meta-analysis.

Authors:  Eri Yin-Soe Aung; Maha Khan; Norman Williams; Usman Raja; Mohamad Hamady
Journal:  Cardiovasc Intervent Radiol       Date:  2022-07-12       Impact factor: 2.797

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.